^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes.

Excerpt:
Advanced NSCLC patients with concomitant EGFR mutation and MET overexpression have significantly low RR with EGFR-TKIs, indicating that MET overexpression potentially causes intrinsic resistance to EGFR-TKIs.